Jiangsu Sihuan Bioengineering Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2019
April 15, 2020 at 05:57 pm IST
Share
Jiangsu Sihuan Bioengineering Co. Ltd. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was CNY 417.878 million compared to CNY 395.514 million a year ago. Operating income was CNY 28.065 million compared to operating loss of CNY 28.807 million a year ago. Net income was CNY 14.330 million compared to net loss of CNY 29.439 million a year ago. Basic earnings per share from continuing operations was CNY 0.0139 compared to basic loss per share from continuing operations of CNY 0.0286 a year ago.
JIANGSU SIHUAN BIOENGINEERING CO., LTD is a China-based company principally engaged in the research, development, manufacture and distribution of medicines and health supplements. The Companyâs main products include interleukin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), tablets, bulk drugs, infusion glass bottles, soft bag infusion, syrup and healthcare products, among others. The Company is also engaged in landscape engineering, maintenance projects, the sale of nursery stocks and other businesses. The Company distributes its products in domestic market and to overseas markets.
JIANGSU SIHUAN BIOENGINEERING CO., LTD 
